Soley Therapeutics secures $200M Series C for oncology programs

Soley Therapeutics has raised $200 million in a Series C round to move its lead oncology assets into the clinic. The funding will also be used to scale its cell stress sensing platform and expand its broader pipeline.

Funding details: $200 million (Series C)

Full Story

South San Francisco–based Soley Therapeutics has announced the close of a $200 million Series C financing to advance its proprietary cell stress sensing platform and bring its first oncology programs into clinical development. The new capital will support IND-enabling work and early clinical trials for two internally discovered cancer assets, including a lead program for acute myeloid leukemia that is expected to file an IND in 2026, and a second program targeting solid tumors.

The round was led by Surveyor Capital, a Citadel company, with participation from new investors HRTG Partners and RWN Management. Existing backers also joined the round, including Breyer Capital, Doug Leone Family Fund, and GordonMD Global Investments, along with other undisclosed investors.

Soley’s technology platform captures time-based cellular stress responses across thousands of features in human cells and converts this data into structured signatures using proprietary computer vision and AI models. The system allows the company to screen hundreds of thousands of compounds each week and generate reproducible data at scale through in-house automation and robotics, accelerating discovery and drug design.

According to co-founder and CEO Yerem Yeghiazarians, the company was built to directly observe how living human cells respond to drugs and translate those insights into new medicines. He noted that the strong backing from life sciences and technology-focused investors validates Soley’s approach as it moves its lead programs into the clinic and continues to expand its platform and pipeline.

Beyond oncology, Soley plans to use the new funding to progress stress-modulating drug candidates for neurodegenerative and metabolic diseases and to further scale its discovery platform. The company also leverages full-stack AI infrastructure through its collaboration with Oracle and NVIDIA to support its research and development efforts.

Source: Company press release (January 7, 2026).